Brainstorm taps Minaris to produce NurOwn for Phase 3b trial
Brainstorm Cell Therapeutics is partnering with Minaris Advanced Therapies to manufacture NurOwn (debamestrocel), its investigational cell therapy for…
Articles by Lila Levinson, PhD
ATH-1105 experimental therapy found safe in healthy adults: Trial
ATH-1105, an experimental oral therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, was found to be safe…
Neurosense, awaiting Canada approval, scales PrimeC production
Neurosense Therapeutics said it’s scaled production of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS), to commercial levels…
Eli Lilly licensing AIchemab’s ALS antibody therapy in $415M deal
Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for…
FDA clears expanded access program for SPG302 in ALS patients
Note: This story was updated May 13, 2025, to correct information about the company’s clinical trials. Spinogenix has received…
IPL344 slows ALS progression in trial, data suggest
Daily treatment with IPL344 for up to three years was safe and appeared to slow amyotrophic lateral sclerosis…
ALS Association, Schoox partner to provide ALS education resources
The ALS Association is teaming with the workplace learning company Schoox to provide education resources for patients, caregivers,…
In ALS, statin use not related to patient survival, study finds
Taking statins to lower cholesterol does not affect survival outcomes for people with amyotrophic lateral sclerosis (ALS), researchers in…